June 2015, CDH WM has invested many times in Loongson, a leading domestic CPU company. The core team of Loongson originated from the Institute of Computer Science, Chinese Academy of Sciences. Under the leadership of the founder, Mr. Hu Weiwu, it has developed independently since 2001. After 20 years of unremitting efforts, Loongson insists on independent innovation, fully masters the core computer technologies such as CPU instruction system, processor IP core, operating system, etc., and creates an independent and open software and hardware ecology and information industry system. Its technology has reached the top level in China and can also be compared with international advanced products. CDH WM will continue to firmly support Loongson to take LoongArch as an opportunity to create a core chapter for the safe development of independent systems, in-depth layout of industrial chain supporting and application ecology, adhere to the construction of a national independent information system , and be a strong foundation for the country's innovative business! Loongson has also been approved by the Shanghai Stock Exchange and the China Securities Regulatory Commission for listing, and will be listed on the Science and Technology Innovation Board in June 2022 to complete the IPO.

CDH invested in Grab, an online car-hailing and food delivery platform company, in Southeast Asia in August 2016. On December 2, 2021, Grab was listed on the NASDAQ in the United States as a SPAC (stock code: Grab). Headquartered in Singapore, Grab currently operates in 428 cities in 8 countries in Southeast Asia. The company is building a "super APP", similar to WeChat or Alipay. Grab's current functions include mobile travel, ordering food or groceries, sending Packages, online payments or access to loans, insurance, wealth management, telehealth, and more.

CDH WM invested twice in China's Beidou navigation satellite positioning chip and solution provider, Allystar, in July 2020 and May 2021. Allystar, formerly known as Huada Electronic Navigation Division under China Electronics Corporation (CEC), was registered and established on December 6, 2016. It is a national high-tech enterprise, Shenzhen high-tech enterprise, Zhongguancun high-tech enterprisec and an enterprise Shenzhen Municipal Government focused on introducing with weak links in the industrial chain in 2016. The core team has more than 30 years of experience in chip R&D and marketization. At present, Allystar focuses on the independent design, research and development, sales and related business of navigation and positioning chips, algorithms and products, aiming at the civilian consumer electronics market and special terminal markets such as the national lifeline industry, the automotive field and IOT.

CDH WM invests in Reindeer Bio, a leading company in the field of cell therapy in China, in August 2021. On June 2, 2022, the China National Medical Products Administration (NMPA) officially accepted the launch of License Application (NDA) of the CAR-T drug Iquilenza injection developed by Reindeer Bio for the treatment of relapsed/refractory multiple myeloma (R/R MM). Iquirenza injection is the first self-developed CAR-T cell therapy product in China. It is the first domestically submitted new drug to be accepted for marketing and is expected to become the first domestically approved autologous chimeric antigen teceptor T cell immunotherapy products targeting BCMA.. The product has been granted "Breakthrough Therapy Drug ( BTD)" designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in February 2021. The approval and marketing of Iquilenx injection will be a milestone event in the field of cell therapy in China.